CF Industries Reports 9M 2026 EBITDA of $3.01B, Including $170M Litigation Gain

What happened

CF Industries reported first nine months 2026 net earnings of $1.78 billion, or $11.60 per diluted share, with adjusted EBITDA of $3.01 billion. The results include a one-time litigation gain of approximately $170 million, which flatters the headline numbers but still leaves underlying EBITDA near $2.84 billion, well above prior mid-cycle expectations. This performance reflects continued strength in nitrogen prices and North American gas cost advantages, contrasting with the base case in the January 2026 DeepValue report that assumed EBITDA would average only ~$2.0 billion through 2027. The company has not yet provided full-year guidance, but the nine-month run rate suggests annualized adjusted EBITDA of roughly $3.8 billion, implying the stock is trading at a much lower EV/EBITDA than the 5.1x seen in January. Investors should scrutinize whether the nitrogen market remains tight enough to sustain these levels or whether the recent strength is cyclical peak earnings that will normalize as new supply comes online.

Implication

The strong EBITDA and earnings suggest CF is generating far more cash than the base case modeled, supporting aggressive capital returns and debt reduction. However, the $170 million litigation gain is non-recurring, and excluding it, adjusted EBITDA of $2.84 billion for nine months still annualizes to ~$3.8 billion, which is nearly double the base case assumption. If nitrogen prices have remained elevated due to supply tightness and strong import demand from India and Brazil, this may persist into 2027, but investors must consider the risk of price normalization as global capacity additions and gas spread compression erode margins. The stock likely trades above the previous $77.49 level, possibly approaching the trim threshold of $95; if so, the risk-reward is less attractive, and investors should wait for a pullback or confirmation of sustained earnings power before adding. Management's capital allocation discipline will be tested: with such high cash generation, they may increase buybacks or dividends, but they must balance this against upcoming Blue Point capex and potential downcycle, so monitor free cash flow after dividends and leverage ratios.

Thesis delta

The original WAIT thesis was based on expectations of EBITDA moderating to ~$2.0B, but actual nine-month 2026 results show EBITDA well above that, indicating the thesis may be too conservative. The underlying business is performing at peak-cycle levels, and if this persists, the stock's valuation is far too cheap, warranting an upgrade to HOLD or BUY. However, the one-time gain and the possibility that nitrogen prices are near a cyclical top temper enthusiasm; the thesis should be revised to reflect a stronger earnings trajectory but with heightened monitoring of price sustainability.